Jeffrey Kindler and Alfonso Zulueta Appointed as Independent Directors to Lupin’s Board

Lupin, a leading pharmaceutical company, has recently welcomed two distinguished individuals, Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta, to its Board as Independent Directors.

Mr. Kindler boasts an illustrious career as a healthcare executive, investor, and advisor, accumulating over four decades of invaluable business experience. He has held prominent leadership roles at renowned companies such as Pfizer, where he served as Chairman & CEO, as well as at McDonald’s Corporation and General Electric Company. Prior to these, he was a partner at the prestigious law firm Williams & Connolly. Currently, Mr. Kindler serves as the CEO of Centrexion Therapeutics, holds a Senior Advisor role at Blackstone, operates as an Operating Partner at ARTIS Ventures, and acts as the Global Chair of GLG Institute. Additionally, he sits on the boards of various companies including Precigen Inc., Perrigo Pharmaceuticals, and Terns Pharmaceuticals. Mr. Kindler holds degrees from Tufts University and Harvard Law School.

Mr. Zulueta brings with him over three decades of experience from Eli Lilly and Company, where he held various leadership positions including Vice President of Global Marketing and President of International. His tenure also saw him as a corporate officer and member of Eli Lilly and Company’s Executive Committee. Currently, Mr. Zulueta serves as the Non-Executive Chairman of the board of directors at Interpharma Investments Limited, and leads CZ Ventures, focusing on startup investments. He also serves on the boards of Glooko, CTS Corporation, and Bridge PayDay Solutions. Mr. Zulueta holds degrees from De La Salle University and the University of Virginia, Darden School of Business.

Vinita Gupta, Lupin’s CEO, expressed her enthusiasm about the appointments, stating, “We are delighted to welcome Jeff and Chito to our board. Their extensive experience in building healthcare institutions, strategic perspectives of our industry, and deep understanding of the evolving global pharmaceutical landscape, will enable us to advance our growth plans in the years to come.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter